GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Chemed Corp (NYSE:CHE) » Definitions » Operating Income
中文

Chemed (Chemed) Operating Income : $343 Mil (TTM As of Dec. 2023)


View and export this data going back to 1982. Start your Free Trial

What is Chemed Operating Income?

Chemed's Operating Income for the three months ended in Dec. 2023 was $108 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 was $343 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Chemed's Operating Income for the three months ended in Dec. 2023 was $108 Mil. Chemed's Revenue for the three months ended in Dec. 2023 was $586 Mil. Therefore, Chemed's Operating Margin % for the quarter that ended in Dec. 2023 was 18.47%.

Good Sign:

Chemed Corp operating margin is expanding. Margin expansion is usually a good sign.

Chemed's 5-Year average Growth Rate for Operating Margin % was 2.40% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Chemed's annualized ROC % for the quarter that ended in Dec. 2023 was 25.10%. Chemed's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 140.73%.


Chemed Operating Income Historical Data

The historical data trend for Chemed's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chemed Operating Income Chart

Chemed Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 266.51 389.68 344.03 347.19 342.83

Chemed Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 97.21 72.50 71.01 91.11 108.21

Chemed Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $343 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Chemed  (NYSE:CHE) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Chemed's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

ROC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=432.856 * ( 1 - 22.09% )/( (1332.469 + 1355.185)/ 2 )
=337.2381096/1343.827
=25.10 %

where

Invested Capital(Q: Sep. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1562.079 - 132.29 - ( 173.15 - max(0, 297.219 - 394.539+173.15))
=1332.469

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1668.095 - 124.117 - ( 263.958 - max(0, 312.05 - 500.843+263.958))
=1355.185

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Chemed's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=463.74/( ( (328.815 + max(-38.215, 0)) + (330.227 + max(-20.83, 0)) )/ 2 )
=463.74/( ( 328.815 + 330.227 )/ 2 )
=463.74/329.521
=140.73 %

where Working Capital is:

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(168.031 + 12.511 + 40.847) - (132.29 + 0 + 127.314)
=-38.215

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(181.511 + 12.004 + 43.37) - (124.117 + 0 + 133.598)
=-20.83

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Chemed's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as:

Operating Margin %=Operating Income (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=108.214/585.912
=18.47 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Chemed Operating Income Related Terms

Thank you for viewing the detailed overview of Chemed's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Chemed (Chemed) Business Description

Traded in Other Exchanges
Address
255 East Fifth Street, Suite 2600, Cincinnati, OH, USA, 45202-4726
Chemed Corp operates subsidiaries in two main segments: VITAS and Roto-Rooter. The VITAS segment generates the majority of the firm's revenue. It provides hospice and palliative-care services to patients with terminal illnesses through a network of physicians, registered nurses, home health aides, social workers, and volunteers. The vast majority of the segment's revenue is received from the Medicare and Medicaid reimbursement programs. The Roto-Rooter segment provides plumbing, drain cleaning, water restoration, and related services to residential and commercial customers. Chemed generates the majority of its revenue from business in the United States.
Executives
Kevin J Mcnamara director, officer: president & ceo 2500 CHEMED CENTER, 255 EAST FIFTH ST, CINCINNATI OH 45202
Spencer S Lee officer: vice president 2500 CHEMED CENTER, 255 EAST FIFTH ST, CINCINNATI OH 45202
David Patrick Williams officer: Vice President & CFO
Nicholas Michael Westfall officer: Executive Vice President 8035 PEREGRINE LANE, CINCINNATI OH 45243
Patrick P Grace director 1100 PARK AVE, APT 15C, NEW YORK NY 10128
Eileen P Mccarthy director 3515 78TH STREET, #2, JACKSON HEIGHTS NY 11372
Michael D Witzeman officer: vice president and controller 255 E 5TH STREET, SUITE 2600, CINCINNATI OH 45202
Mount John Meredith Jr. director 2906 MABRY ROAD NE, ATLANTA GA 30319
Donald E Saunders director 306 MIANI TRAIL, OXFORD OH 45056
Christopher J Heaney director 101 S. FORT LAUDERDALE BEACH BLVD., APARTMENT 1602, FORT LAUDERDALE FL 33316
Ron Delyons director 2692 MADISON ROAD, SUITE N1-313, CINCINNATI OH 45208
Naomi C Dallob officer: VP and Chief Legal Officer 255 EAST FIFTH STREET, SUITE 2600, CINCINNATI OH 45202
Thomas C Hutton director, officer: vice president ONE ROCKEFELLER PLAZA, STE 1510, NEW YORK NY 10020
Walsh George J Iii director ONE CHASE MANHATTAN PLAZA, NEW YORK NY 10005
Andrea R Lindell director